Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo® - GlobeNewswire

Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo®  GlobeNewswire

JATENZO® is a first-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult hypogonadal ...



Comments

Post a Comment

Popular posts from this blog